Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a sell rating in a report issued on Monday, Zacks.com reports.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

DCPH has been the subject of a number of other reports. ValuEngine downgraded shares of Woodward, Inc.Common Stock from a buy rating to a hold rating in a research report on Tuesday, April 9th. BidaskClub downgraded shares of Weyco Group from a sell rating to a strong sell rating in a research report on Saturday, July 13th. Finally, Piper Jaffray Companies downgraded shares of Cypress Semiconductor from an overweight rating to a neutral rating in a research report on Monday, June 3rd. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Deciphera Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $41.00.

NASDAQ DCPH opened at $20.55 on Monday. The company has a current ratio of 9.55, a quick ratio of 9.55 and a debt-to-equity ratio of 0.01. Deciphera Pharmaceuticals has a 1-year low of $18.55 and a 1-year high of $41.00. The company has a 50 day simple moving average of $22.85. The firm has a market capitalization of $798.53 million, a P/E ratio of -7.29 and a beta of 2.35.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Thursday, May 9th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.41). Research analysts predict that Deciphera Pharmaceuticals will post -4.57 earnings per share for the current year.

In related news, CFO Thomas Patrick Kelly sold 1,473 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $25.06, for a total value of $36,913.38. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 17,250 shares of company stock worth $403,813 over the last three months. 7.02% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its stake in Deciphera Pharmaceuticals by 61,033.3% in the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock valued at $43,000 after acquiring an additional 1,831 shares during the last quarter. Great West Life Assurance Co. Can bought a new stake in shares of Deciphera Pharmaceuticals during the fourth quarter worth $50,000. Rhumbline Advisers grew its stake in shares of Deciphera Pharmaceuticals by 53.6% during the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after buying an additional 4,000 shares during the last quarter. Squarepoint Ops LLC grew its stake in shares of Deciphera Pharmaceuticals by 18.1% during the fourth quarter. Squarepoint Ops LLC now owns 39,306 shares of the company’s stock worth $825,000 after buying an additional 6,028 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Deciphera Pharmaceuticals by 187.7% during the fourth quarter. Barclays PLC now owns 13,908 shares of the company’s stock worth $292,000 after buying an additional 9,073 shares during the last quarter. 58.89% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: Correction

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit